Novartis del-desiran Phase III failure fallout
Analysis based on 21 articles · First reported Sep 08, 2026 · Last updated Sep 11, 2026
The trial failure triggered a sharp sell-off in Novartis shares, wiping tens of billions of dollars of market value and raising doubts about the company's M&A-driven pipeline strategy ahead of looming patent expiries. It also spilled over to other muscular dystrophy drug developers such as Dyne Therapeutics and Sarepta Therapeutics, while keeping investor focus on upcoming remibrutinib data as the next key catalyst.
Novartis announced on September 8, 2026 that its Phase III HARBOR study of del-desiran, an antibody oligonucleotide conjugate for myotonic dystrophy type 1 (DM1), failed to show statistically significant improvement versus placebo on the primary endpoint of video hand opening time. The drug was acquired through Novartis' roughly $12 billion purchase of Avidity Biosciences. It was the second major pipeline setback in days, following the failure of the cholesterol drug pelacarsen, and Novartis shares fell about 9-11% in one of the company's worst trading days on record, reportedly wiping roughly 24 billion Switzerland — Swiss francs (about $29.6 billion) off its market value and erasing gains made since the start of the year. The failure increases pressure on CEO Shar Narasimhan and his M&A-led pipeline strategy, with investors including Artisan Partners Asset Management, Union Investment, Verso Investment Management, DJE Kapital, Bellevue Asset Management and Arctic Asset Management questioning the Avidity deal and calling for more disciplined, smaller bolt-on acquisitions and better board oversight. Novartis reiterated its 5-6% five-year sales CAGR guidance for 2025-2030 and continues to advance other Avidity AOC therapies, including del-zota, which received FDA priority review in DMD44, and del-brax in FSHD. The next major catalyst is detailed remibrutinib data in relapsing multiple sclerosis expected at a medical meeting in October. The news also weighed on other muscular dystrophy developers, with Dyne Therapeutics and Sarepta Therapeutics shares falling sharply in US premarket trading.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard